Are Ozempic and Wegovy the same drug?
Yes — at the molecular level, Ozempic and Wegovy are the same medicine. Both contain a single active ingredient: semaglutide, a GLP-1 receptor agonist. There is no second molecule, no different chemistry, and no different mechanism of action between them. When people ask "Ozempic vs Wegovy," they are really asking about two brand names for one drug.
This is genuinely unusual, and it is the source of most of the confusion around these two products. We are used to "drug A vs drug B" comparisons meaning two distinct compounds that work in different ways. Here, the receptor target, the way the drug suppresses appetite and slows gastric emptying, and the underlying pharmacology are identical because the molecule is identical.
So if the drug is the same, why are there two names? Because the manufacturer brought semaglutide to market for two different approved purposes, at two different maximum doses, with two different labels. That is the entire substance of this comparison — not chemistry, but indication, dose, and the regulatory paperwork that governs how each version is meant to be used.
It helps to hold two ideas at once: the active ingredient is genuinely the same, and yet the two are not the same product. "Same molecule" answers a chemistry question; "different label" answers a regulatory and clinical one. The rest of this page works through where those two truths line up and where they pull apart — the approved use, the studied dose, the evidence base behind each, and why none of that makes the two casually swappable.
What is actually different between Ozempic and Wegovy?
The real differences are the FDA-approved use and the maximum dose. Ozempic was approved by the FDA in 2017 for type 2 diabetes. Wegovy was approved in 2021 for chronic weight management. Same molecule, two different approved indications — and that distinction is what the brand names exist to mark.
The dose ceiling is the other concrete difference. Ozempic's approved doses run from a 0.25 mg starting dose up through 0.5 mg, 1 mg, and a maximum of 2 mg once weekly. Wegovy titrates higher — through 0.25, 0.5, 1, and 1.7 mg up to a maintenance dose of 2.4 mg once weekly, which is above Ozempic's ceiling. The higher target dose reflects the fact that Wegovy was developed and studied specifically for weight management.
Everything else flows from those two facts. Because Wegovy is the weight-management brand studied at 2.4 mg, that is where the large dedicated weight-loss trial sits. Because Ozempic is the diabetes brand, that is where the diabetes-focused cardiovascular outcomes data sit. The molecule is one and the same; the label, the studied dose, and the indication are what differ.
What does the weight-loss evidence show?
The headline weight-management evidence for semaglutide comes from the STEP 1 trial, which studied the 2.4 mg dose — the Wegovy maintenance dose. In STEP 1, participants lost a mean of 14.9% of their body weight at 68 weeks, compared with 2.4% in the placebo group. That is a large, clinically meaningful difference and is the basis for semaglutide's reputation as a weight-management therapy.
It is worth being precise about what that trial does and does not say. STEP 1 tested the 2.4 mg dose, the dose Wegovy is titrated to — not Ozempic's 2 mg ceiling. So the 14.9% figure belongs to the weight-management brand and dose specifically. Ozempic, dosed for diabetes up to 2 mg, was not the subject of that particular trial, even though it is the same molecule.
This is the cleanest illustration of the "same drug, different label" point. The weight-loss number is tied to a specific dose studied in a specific population for a specific approved use. The molecule could be described as semaglutide either way, but the evidence, the dose, and the indication are what give the Wegovy brand its weight-management identity.
What does the cardiovascular evidence show?
Semaglutide has cardiovascular outcomes data on both sides of the indication divide. In people with type 2 diabetes, the SUSTAIN-6 trial found that semaglutide reduced major adverse cardiovascular events (MACE), with a hazard ratio of 0.74 versus placebo. That diabetes-population evidence sits with the brand approved for diabetes.
More recently, the SELECT trial studied semaglutide in people with obesity but without diabetes who had established cardiovascular disease, and found a reduction in major adverse cardiovascular events — 6.5% on semaglutide versus 8.0% on placebo, a hazard ratio of 0.80. On the strength of that kind of evidence, Wegovy carries a cardiovascular risk-reduction indication, while Ozempic is the diabetes brand.
The takeaway is not that one brand "has heart benefits" and the other does not — it is the same molecule — but that the cardiovascular evidence and the corresponding label language map onto the two different approved populations these brands serve. Which body of evidence is relevant to a given person depends on that person's diagnosis, which is a clinician's assessment, not a branding question.
How are Ozempic and Wegovy dosed?
Both are once-weekly subcutaneous injections of semaglutide, and both follow the same titrate-slowly principle: start low, step up gradually, and let the body adapt to limit gastrointestinal side effects. The starting dose for both is 0.25 mg once weekly, which is an introductory dose meant to limit nausea rather than to drive a therapeutic effect.
From there the two diverge at the top. Ozempic steps up to 0.5 mg, then 1 mg, and can go up to a maximum of 2 mg once weekly — the approved range for type 2 diabetes. Wegovy continues past that point: 0.25 → 0.5 → 1 → 1.7 → 2.4 mg once weekly, with 2.4 mg as the maintenance dose for chronic weight management. That higher ceiling is the single biggest dosing difference and it is built into each brand's approved label.
Because the dose schedules differ, the two are not casually interchangeable even though the molecule is the same. The titration path, the target dose, and the device each correspond to a specific approved use, and matching them to a person's diagnosis and goals is exactly the kind of decision a prescriber is responsible for.
Do Ozempic and Wegovy have the same side effects?
Largely yes, because the side-effect profile follows the molecule, and the molecule is the same. Both share the dose-dependent gastrointestinal profile common to GLP-1 receptor agonists: nausea, diarrhea, vomiting, and constipation are the most frequently reported effects, and in both they tend to be most noticeable early and to ease as the dose is escalated gradually.
The gradual titration schedules — starting at 0.25 mg and stepping up over weeks — exist in large part to manage exactly these effects. Going up in dose too quickly tends to worsen the gastrointestinal symptoms, which is why both brands build in a slow ramp rather than starting at the target dose. Because Wegovy titrates to a higher maximum, its highest dose simply sits further along that same dose-dependent curve.
As with any prescription medicine, the full safety picture — including less common but important warnings — belongs in the prescribing information and in a conversation with a licensed clinician, who can weigh an individual's history and monitor for problems over time.
One practical point follows from the shared profile: a side effect experienced on one brand is, in principle, a side effect of semaglutide itself rather than of a brand-specific formulation, because the active ingredient is identical. That is useful context for a prescriber, but it is not a reason to self-adjust or self-substitute — how to respond to side effects, including whether to hold, slow, or change a dose, is a clinical judgment.
Why can't you just swap one for the other?
It is tempting to conclude that, because Ozempic and Wegovy are both semaglutide, they are interchangeable. They are not — and treating them as interchangeable misses the point of having two labels. Each brand is approved for a specific use, studied at a specific dose, and supplied with its own dosing schedule and device. Those distinctions are not cosmetic; they are the regulatory framework that defines how each version is meant to be used.
Whether a given person should be on the diabetes brand or the weight-management brand, at what dose, and whether any change makes sense is a clinical decision that depends on diagnosis, history, goals, and monitoring. Nothing here is a recommendation to switch, to substitute one for the other, or to adjust a dose on your own. The shared molecule does not collapse two distinct, separately approved products into one.
In short: same active ingredient, two different approved products. The fact that the chemistry is identical is genuinely useful for understanding what these drugs are — but it is a clinician, not a brand name, who decides which approved use, brand, and dose fit a particular person. Defer that decision to a licensed prescriber.
Tracking either on PeptidePanel
Whichever brand a clinician prescribes, the day-to-day work is the same: log the weekly dose, watch the biomarkers that matter (for many people that is weight trend, HbA1c, and lipids), and catch side effects early. PeptidePanel is the neutral tracking layer for that — it records the protocol your clinician sets, charts your bloodwork against reference ranges, and reminds you when a dose or a lab is due.
Because Ozempic and Wegovy share a molecule but follow different titration schedules, an accurate record of exactly which brand and dose you are on — and how you are responding — is genuinely useful information for your prescriber. PeptidePanel does not sell, source, or supply any medication. It is a monitoring tool for protocols that a qualified prescriber has put you on.